Vapotherm (NYSE:VAPO) Lowered to “Neutral” at BTIG Research

Vapotherm (NYSE:VAPOGet Rating) was downgraded by stock analysts at BTIG Research from a “buy” rating to a “neutral” rating in a research note issued to investors on Thursday, The Fly reports.

VAPO has been the topic of a number of other reports. William Blair cut Vapotherm from an “outperform” rating to a “market perform” rating in a research report on Thursday. Canaccord Genuity Group downgraded Vapotherm from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $12.00 to $5.00 in a research note on Friday, May 6th. Canaccord Genuity Group lowered Vapotherm from a “buy” rating to a “hold” rating and decreased their price target for the company from $12.00 to $5.00 in a report on Friday, May 6th. Finally, Piper Sandler lowered their price target on Vapotherm from $2.50 to $2.00 and set an “underweight” rating for the company in a research report on Thursday. One equities research analyst has rated the stock with a sell rating and four have given a hold rating to the stock. According to data from MarketBeat, Vapotherm presently has a consensus rating of “Hold” and an average target price of $4.75.

Vapotherm Price Performance

VAPO opened at $1.80 on Thursday. Vapotherm has a 12-month low of $1.66 and a 12-month high of $31.87. The company has a current ratio of 5.37, a quick ratio of 3.75 and a debt-to-equity ratio of 1.79. The stock has a fifty day simple moving average of $2.56 and a two-hundred day simple moving average of $7.93. The company has a market cap of $47.82 million, a price-to-earnings ratio of -0.49 and a beta of -0.22.

Vapotherm (NYSE:VAPOGet Rating) last issued its quarterly earnings results on Wednesday, May 4th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.24). Vapotherm had a negative net margin of 102.94% and a negative return on equity of 114.14%. The company had revenue of $21.62 million for the quarter, compared to the consensus estimate of $21.03 million. During the same quarter in the previous year, the business earned ($0.40) earnings per share. Vapotherm’s revenue was down 33.1% compared to the same quarter last year. Research analysts predict that Vapotherm will post -3.07 earnings per share for the current fiscal year.

Insider Activity at Vapotherm

In related news, Director James W. Liken purchased 10,000 shares of the firm’s stock in a transaction on Wednesday, May 11th. The stock was bought at an average cost of $2.98 per share, with a total value of $29,800.00. Following the completion of the acquisition, the director now owns 134,378 shares of the company’s stock, valued at approximately $400,446.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have bought a total of 40,000 shares of company stock worth $122,700 over the last quarter. Insiders own 12.80% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Adage Capital Partners GP L.L.C. lifted its stake in Vapotherm by 12.5% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 450,000 shares of the company’s stock worth $9,320,000 after acquiring an additional 50,000 shares in the last quarter. Crow s Nest Holdings LP purchased a new stake in shares of Vapotherm in the fourth quarter valued at approximately $11,422,000. Sio Capital Management LLC purchased a new stake in shares of Vapotherm in the fourth quarter valued at approximately $3,728,000. RiverVest Venture Management LLC raised its holdings in Vapotherm by 0.6% during the fourth quarter. RiverVest Venture Management LLC now owns 407,166 shares of the company’s stock worth $8,432,000 after purchasing an additional 2,535 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC acquired a new position in Vapotherm during the fourth quarter worth $10,339,000. 69.67% of the stock is owned by institutional investors and hedge funds.

About Vapotherm

(Get Rating)

Vapotherm, Inc, a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface.

Featured Stories

The Fly logo

Analyst Recommendations for Vapotherm (NYSE:VAPO)

Want More Great Investing Ideas?

Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with's FREE daily email newsletter.